[moc::"[[MOC Special Topics - Lung]]"]
>[!title]
> ANITA Douillard IJROBP '08](https://www.sciencedirect.com/science/article/pii/S0360301608001946?via%3Dihub):

>[!intervention]
> {± adjuvant CDDP and vinorelbine.}

# Study
- 840 patients #pimp
	- completely resected #pimp
	- Stage IB-IIIA NSCLC #pimp
	- Primary outcome: OS #pimp
- Treatment
	- Adj Vinorelbine+CisP v Control #pimp
	- RT not required or excluded (usually given for pN+) #pimp
		- 25% of patients
		- ~1.5x as common in the adjChemo group
		- 45-60Gy, conventional
# Results
- Adjuvant Chemo → better OS (HR 0.8) #pimp
	- Median OS 44 → 66 months #pimp
	- ![[img_ANITA_results1.png#invert]]

| Variable | UVA | MVA |
| ---- | ---- | ---- |
| >55 | 0.76 | 0.76 |
| Stage IIIA | 0.64 | 0.63 |
| N+ | 0.61 | 0.60 |
| Chemo | - | 0.76 |

- Unplanned Subgroup: 2008
	- UVA: HR 1.34 (detrimental)
	- ![[img_ANITA_results2.png#invert]]
	- pN2: 
		- OS benefit for RT, regardless of chemo.
		- ![[img_ANITA_results3.png#invert]]
	- pN1:
		- OS benefit for RT without chemo
		- OS detriment for RT with chemo
		- ![[img_ANITA_results4.png#invert]]

>[!summary]
> - Unconditional recommendation for adjuvant Chemo with Cisplatin+Vinorelbine. 
>- Subgroup shows benefit for pN2 and pN1 without adjChemo
>^summary

# PDF
![[02. ANITA PORT Analysis.pdf]]